Fusion Pharmaceuticals Inc   (FUSN)
Other Ticker:  
Price: $10.7900 $-1.20 -10.008%
Day's High: $12.9 Week Perf: -13.68 %
Day's Low: $ 10.79 30 Day Perf: -2.97 %
Volume (M): 1,254 52 Wk High: $ 13.99
Volume (M$): $ 13,532 52 Wk Avg: $5.25
Open: $12.40 52 Wk Low: $2.31

 Market Capitalization (Millions $) 745
 Shares Outstanding (Millions) 69
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) 84
 Cash Flow (TTM) (Millions $) -79
 Capital Exp. (TTM) (Millions $) 3

Fusion Pharmaceuticals Inc
Fusion Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing and commercializing targeted alpha therapies for the treatment of cancer. The company uses novel approaches that combine targeted alpha therapeutics with radiation-guided drug delivery to specifically target cancer cells while sparing healthy tissues.

Fusion Pharmaceuticals utilizes its proprietary Fast-Clear linker technology platform to connect alpha-emitting isotopes with targeting molecules, such as antibodies or peptides. This approach allows them to deliver high doses of radiation directly to cancer cells, potentially enhancing the efficacy of therapy and minimizing side effects.

By developing innovative therapies, Fusion Pharmaceuticals aims to address critical unmet needs in oncology and provide safer and more effective treatment options for cancer patients. The company is actively advancing its pipeline of targeted alpha therapies, with various candidates in preclinical and clinical development stages.

   Company Address: 270 Longwood Rd., S. Hamilton 0 ON
   Company Phone Number: 799-0891   Stock Exchange / Ticker: NASDAQ FUSN
   FUSN is expected to report next financial results on March 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Fusion Pharmaceuticals Inc

Strong Financial Performance Positions Fusion Pharmaceuticals Inc for Potential Growth

Fusion Pharmaceuticals Inc, a NASDAQ-listed company, has experienced a slight drop in stock price over the past five trading days. However, the stock has performed exceptionally well throughout the year, delivering a year-to-date performance of 40.63%. With a current trading position sitting comfortably above its 52-week average, Fusion Pharmaceuticals is poised for potential growth. Let's delve into the company's recent financial results and explore how these figures might impact its future trajectory.
1. Improved Earnings per Share (EPS):
In the third quarter of 2023, Fusion Pharmaceuticals reported a decrease in loss per share from $-0.55 to $-0.25, compared to the same period last year. This represents a significant improvement in EPS. Additionally, compared to the previous quarter, the company showcased further growth in EPS, which increased from $-0.38 per share. These positive trends indicate that Fusion Pharmaceuticals' financial performance is gradually moving in the right direction, signaling potential stability in the near future.

Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc Struggles in Second Quarter of 2023, but Shows Signs of Improvement

As a stock market journalist, I have been closely following the recent financial results of Fusion Pharmaceuticals Inc. The company's performance has shown some mixed trends over the past financial quarter ending June 30, 2023.
Firstly, FUSN has managed to decrease their loss per share, which is a positive move for the company. In comparison to the previous year, the loss per share has reduced from $-0.44 to $-0.38. Additionally, the income per share has improved from $-0.45 per share in the previous quarter.

Fusion Pharmaceuticals Inc

Fusion Pharmaceuticals Inc. Shows Improvement with a $0.45 Per Share Loss in Q1 2023, Despite Industry Challenges

Fusion Pharmaceuticals Inc, a developer of radiopharmaceutical therapies, has announced its financial results for the fiscal span ending March 31, 2023. The company has reported a loss of $0.45 per share, which is an improvement from last year's loss of $0.46 per share. However, earnings per share have fallen from $3.31 per share in the prior quarter.
The company has suffered a sharp decline in revenue from $0.59 million in the same quarter a year before to $0.03 million, marking a decrease of -95.214%. Sequentially, the revenue tumbled by -80% from $0.14 million. These results are reflective of the challenges faced by the biotech industry due to delays in clinical trials and regulatory approvals concerning the COVID-19 pandemic.


Fusion Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com